Christina Brzezniak1, Sacha Satram-Hoang2, Hans-Peter Goertz3, Carolina Reyes3, Ashok Gunuganti2, Christopher Gallagher4, Corey A Carter5. 1. John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD, 20889-5600, USA. 2. Q.D. Research, Inc, 8777 Auburn Folsom Road Suite C501, Granite Bay, 95746, CA, USA. 3. Genentech, Inc, 1 DNA Way, South San Francisco, 94080, CA, USA. 4. Washington Cancer Institute, MedStar Washington Hospital Center, 110 Irving St NW C2149, Washington, 20010, DC, USA. 5. John P. Murtha Cancer Center, Walter Reed National Military Medical Center, 8901 Wisconsin Ave, Bethesda, MD, 20889-5600, USA. corey.a.carter.mil@mail.mil.
Abstract
BACKGROUND: Lung cancer is the leading cause of cancer-related death in the United States (US) Military and worldwide, with non-small cell lung cancer (NSCLC) accounting for 87 % of cases. OBJECTIVES: Using a US military cohort who receives equal and open access to healthcare, we sought to examine demographic, clinical features and outcomes with NSCLC. DESIGN AND PARTICIPANTS: We conducted a retrospective cohort analysis of 4,751 patients, aged ≥ 18 years and diagnosed with a first primary NSCLC between 1 January 2003 and 31 December 2013 in the US Department of Defense (DoD) cancer registry. MAIN MEASURES: Differences by patient and disease characteristics were compared using Chi-square and t-test. Kaplan Meier curves and Cox proportional hazards regression assessed overall survival. RESULTS: The mean age at diagnosis was 66 years, 64 % were male, 72 % were Caucasian, 41 % were diagnosed at early stage, 77 % received treatment and 82 % had a history of tobacco use. Mean age at diagnosis was highest among Caucasians (67 years) and lowest among African Americans (AA; 62 years). Asian/Pacific Islanders (PI) were more likely to be female (p < 0.0001), have adenocarcinoma histology (p = 0.0003) and less likely to have a history of tobacco use (p < 0.0001) compared to other racial/ethnic groups. In multivariable survival analysis, older age, male gender, increasing stage, not receiving treatment, and tobacco history were associated with higher mortality risk. Untreated patients exhibited a 39 % higher mortality risk compared to treated patients (HR = 1.39; 95%CI = 1.23-1.57). Compared to Caucasian patients, Asian/PIs demonstrated a 20 % lower risk of death (HR = 0.80; 95%CI = 0.66-0.96). There was no difference in mortality risk between AAs and Hispanics compared to Caucasians. CONCLUSION: The lack of significant outcome disparity between AAs and Caucasians and the earlier stage at diagnosis than usually seen in civilian populations suggest that equal access to healthcare may play a role in early detection and survival.
BACKGROUND: Lung cancer is the leading cause of cancer-related death in the United States (US) Military and worldwide, with non-small cell lung cancer (NSCLC) accounting for 87 % of cases. OBJECTIVES: Using a US military cohort who receives equal and open access to healthcare, we sought to examine demographic, clinical features and outcomes with NSCLC. DESIGN AND PARTICIPANTS: We conducted a retrospective cohort analysis of 4,751 patients, aged ≥ 18 years and diagnosed with a first primary NSCLC between 1 January 2003 and 31 December 2013 in the US Department of Defense (DoD) cancer registry. MAIN MEASURES: Differences by patient and disease characteristics were compared using Chi-square and t-test. Kaplan Meier curves and Cox proportional hazards regression assessed overall survival. RESULTS: The mean age at diagnosis was 66 years, 64 % were male, 72 % were Caucasian, 41 % were diagnosed at early stage, 77 % received treatment and 82 % had a history of tobacco use. Mean age at diagnosis was highest among Caucasians (67 years) and lowest among African Americans (AA; 62 years). Asian/Pacific Islanders (PI) were more likely to be female (p < 0.0001), have adenocarcinoma histology (p = 0.0003) and less likely to have a history of tobacco use (p < 0.0001) compared to other racial/ethnic groups. In multivariable survival analysis, older age, male gender, increasing stage, not receiving treatment, and tobacco history were associated with higher mortality risk. Untreated patients exhibited a 39 % higher mortality risk compared to treated patients (HR = 1.39; 95%CI = 1.23-1.57). Compared to Caucasian patients, Asian/PIs demonstrated a 20 % lower risk of death (HR = 0.80; 95%CI = 0.66-0.96). There was no difference in mortality risk between AAs and Hispanics compared to Caucasians. CONCLUSION: The lack of significant outcome disparity between AAs and Caucasians and the earlier stage at diagnosis than usually seen in civilian populations suggest that equal access to healthcare may play a role in early detection and survival.
Authors: Charles R Mulligan; Amir D Meram; Courtney D Proctor; Hongyu Wu; Kangmin Zhu; Aizen J Marrogi Journal: Cancer Epidemiol Biomarkers Prev Date: 2006-01 Impact factor: 4.254
Authors: A William Blackstock; James E Herndon; Electra D Paskett; Antonius A Miller; Christopher Lathan; Harvey B Niell; Mark A Socinski; Everett E Vokes; Mark R Green Journal: J Clin Oncol Date: 2005-12-19 Impact factor: 44.544
Authors: J O Ebbert; B A Williams; Z Sun; M C Aubry; J A Wampfler; Y I Garces; R L Meyer; P Yang Journal: Lung Cancer Date: 2005-02 Impact factor: 5.705
Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245
Authors: Taofeek K Owonikoko; Camille C Ragin; Chandra P Belani; Ana B Oton; William E Gooding; Emanuela Taioli; Suresh S Ramalingam Journal: J Clin Oncol Date: 2007-12-10 Impact factor: 44.544
Authors: Timothy R Church; William C Black; Denise R Aberle; Christine D Berg; Kathy L Clingan; Fenghai Duan; Richard M Fagerstrom; Ilana F Gareen; David S Gierada; Gordon C Jones; Irene Mahon; Pamela M Marcus; JoRean D Sicks; Amanda Jain; Sarah Baum Journal: N Engl J Med Date: 2013-05-23 Impact factor: 91.245
Authors: Jie Lin; Katherine A McGlynn; Corey A Carter; Joel A Nations; William F Anderson; Craig D Shriver; Kangmin Zhu Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-08-26 Impact factor: 4.254
Authors: Tommy Mullaney; Xiang Zhou; Jane J Liu; Kristin L Ayers; Kyeryoung Lee; Meng Ma; Scott Jones; Li Li; Arielle Redfern; Whitney Jappe; Zongzhi Liu; Howard Goldsweig; Kamlesh K Yadav; Nicholas Hahner; Matthew Dietz; Michelle Zimmerman; Tony Prentice; Scott Newman; Rajwanth Veluswamy; Juan Wisnivesky; Fred R Hirsch; William K Oh; Shuyu D Li; Eric E Schadt; Rong Chen Journal: Oncologist Date: 2021-05-11
Authors: Anish J Mehta; Shannon Stock; Stacy W Gray; David R Nerenz; John Z Ayanian; Nancy L Keating Journal: Cancer Med Date: 2018-09-28 Impact factor: 4.452